

Disclosures

Consultant for: Alkermes, Drug Delivery LLC, Nirsum Labs, Indivior, American Society of Addiction Medicine (ASAM), National Association of Drug Court Professionals

Research funding from: Alkermes, National Institute on Drug Abuse, University of MD, Indivior

Medications for research studies: Alkermes, Braeburn, Indivior

1

2

Outline

- Scope of the problem
- Treatment

5


- Medications (MAT / MOUD)
- Family involvement
- Innovative, developmentally-informed approaches

Background and overview

- OUD is an advanced, malignant form of SUD, usually beginning in youth
- Adolescents and young adults are extremely vulnerable; Young adults are disproportionately affected; Adolescent involvement is increasing
- There is evidence and consensus for medications in OUD (MOUD) in youth, but dissemination is poor due to problems with capacity, misinformation, and prejudice
- Broader use of MOUD is vital as a cornerstone of treatment. MOUD-forward approaches
 are especially important.
- But youth have worse outcomes than mature adults because of developmental vulnerability and treatment system limitations
- Improved strategies that target treatment capacity, engagement, retention and medication adherence could help. The Youth Opioid Recovery Support (YORS) and BOND interventions and others have promise as developmentally-informed approaches

3

4






Intervention for youth substance use is **Prevention** for youth OUD

- Addiction a developmental disorder of pediatric onset
- The vast majority of youth who initiate opioids have problems with other substances first
- · Earlier onset associated with worse outcomes
- Earlier intervention associated with better outcomes
- Opioid addiction as an advanced stage in progression of illness
- Intervention for non-opioid SUD prior to opioid initiation cannabis, alcohol, nicotine is OUD prevention

MOUD for adolescents and young adults Summary of the evidence

- · Buprenorphine clearly effective
- XR-NTX promising, but less youth-specific research
- Outcomes very good, not as good as for older adults, but far batter than without medication
- Longer is better; no evidence for time limitation
- No signal for safety or efficacy problems based on age
- MOUD first line; No evidence for fail-first
- MOUD should be STANDARD OF CARE

7



Medications promote retention for youth (But poor uptake)

Youth 13-22, Medicaid claims 26% received any medication (5% for age <18 yrs).

Log-rank test: P4.001

Received medication

Received medication

Hadland et al. JAMA Pediatrics 2018

9 10

If only it were that easy We found this in your brain.*

How should we help this young person?

- 18 (or 16 or 25), M or F
- Onset cannabis age 13
- Onset nasal (or smoked) "percocet" use 17, progressing to daily use with withdrawal within 8 months, injection fentanyl 6 months later
- 2 episodes residential tx, 1 AMA, 1 completed, but no continuing care
- Buprenorphine treatment (monthly supply Rx x 4), took erratically, sold half
- Presents in crisis seeking detox ("Can I be out of here by Friday?")

11 1

2

12

Features of youth opioid treatment

- Developmental barriers to treatment engagement
 - Invincibility
 - Immaturity
 - · Motivation and treatment appeal
 - Less salience of consequences
- Strong salience of burdens of treatment
- · Variable effectiveness of family leverage • Pushback against sense of parental dependence and restriction
- Prominence of co-morbidity



Youth have worse outcomes than adults Relapse: XBOT secondary analysis 0.8 0.4 0.2 223 50 12 203 193 0 (185) 40 36 0 (33) 16 20 24

13

MOUD feasible for youth in real world But poor adherence in community treatment

- Treatment received in acute residential followed by multiple community providers, youth 15-21, N=288
 - XRNTX 28%, Bup 33%, No meds 39%
- Over 6 months following residential discharge low rates of MOUD use:
 - XRNTX: mean doses 1.3
 41% 1st OP dose

 - 12% 3rd OP dose
 - 2% 6th OP dose
 - · Bup: mean days 57

Family Engagement: Historical Barriers

- Normative pushback against sense of parental dependence and restriction
- Clinicians: lack of training, competence,
- Focus on internal transformation
- Preoccupying focus on "enabling"
- Over-rigid concern with confidentiality



15

16

14

Can families find a balance?



Desperate for immediate change, trying everything, sacrificing time and money, zero tolerance, going for the "nuclear option", kicked out of the house TODAY

Helpless. It doesn't matte what I do, my child is going to use. There's no point in trying. Don't ask, don't tell. Don't let me catch you using, I don't Want to know about it

Rationale for family involvement Both families and patients need a recipe for treatment with role definitions, expectations, and responsibilities Families have core competence, deep connections, special powers of persuasion and natural leverage that we as clinicians don't have Family mobilization - "Medicine may help with the receptors, but you still have to parent this difficult young person" Encouragement of emerging patient autonomy and self-efficacy is compatible with empowerment of families

Principles of Family Negotiation The Art of the Deal

- · Pick your battles
- Know your leverage
- · You gotta give to get
- You have more juice than you realize
- Keep your eyes on the prize



Example of Innovative Intervention
Youth Opioid Recovery Support (YORS)

Assertive
Outreach

Family
Involvement

Medication
Home Delivery

Incentives for
Medication

19

Assertive Treatment

Well established for treatment of **chronic illness** in hard-to-reach populations in which medication adherence is a **major barrier**

• TB, HIV, schizophrenia (ACT)



Elements of family sessions

Family **psychoeducation** about OUD, medications, and other treatment

Collaborative treatment agreement between youth, family member, program

Skill building and improving effectiveness: Communication skills; shaping desired behaviors through operant conditioning; picking your battles

How will family know about and help **support** attendance and treatment progress? How will family help **support** medication adherence?

Crisis management -- What is the back-up or rescue plan if there is trouble?

21

22

20

Poster child for family involvement?

- 23 year old male injecting heroin
- 4 inpatient detox admissions over 1.5 years, each time got first dose of extended release naltrexone but never came back for 2nd dose
- Lives with grandmother, team shows up with dose, he says no thank you, she says no not an option, done deal, gets 6 doses over 6 months


"As I learned from growing up, you don't mess with your grandmother. "


- Prince William

Balancing parental and young adult empowerment


- Patient: "Mom, you can't be in here when I'm getting the shot..."
- \bullet Therapist: "Ma'am I think it's best if we provide her privacy for the injection."
- Mother: "Are you kidding me? Of course I am. I'm not leaving this room till I see that medicine go in you..."

23





26



YORS HEAL BRIM Project Yrs 1-2: intervention enhancement, test cycles Yrs 2-5: larger RCT of enhanced YORS Enhancements: Focus groups, interviews, qualitative and quantitative results Medication choice – no brainer Mobile van – 2 thumbs up! Telehealth – 3 thumbs up! reSet m-health app – mixed reviews Parent peer tele-group – strong endorsement from Written feedback "report card" – lukewarm at best




Example of innovative intervention XR-Bup for adolescents

- Helps to address adherence problems
- Maryland medicaid approving on a case by case basis
- · More research needed

28

29 30



Community reinforcement approach and family training (CRAFT)

- · Working primarily with the concerned significant other (CSO)
- Goals:
 - Move the loved one toward treatment
 - Reduce loved one's substance use
 - Improve the CSO's wellbeing
- Methods

32

34

 Communication skills -- be positive, be brief, refer to specific behaviors, use I statements, offer to help, shape behaviors – be behaviors, use i statemente, once se men, on

31



BOND

Building opioid recovery support networks to engage and retain loved ones in medication for OUD

- Moving upstream to engage families in order to engage youth with OUD
- Coaching of families (and other concerned significant others) to get out-of-treatment youth into treatment
- · Recruit concerned significant others
- Outcomes engagement into treatment, MOUD initiation, MOUD retention

33




New adolescent inpatient treatment program Residential treatment program for youth with substance use disorders coming to Baltimore Referrals -- Laura Grant Maryland ! Igrant@marylandtreatment.org MARYLAND TREATMENT CENTERS

36 35

Conclusions A Call to Action

- We are at a crossroads
- We have an existing and emerging toolbox but an alarmingly low level of adoption and utilization
- · Emerging research and clinical consensus support aggressive treatment for OUD across the lifespan with MOUD
- We are saving lives, but we need to do better Developmentally-informed interventions might
- If not now, then when?



Questions? Discussion? Therapeutic optimism remains one of our best tools!

37 38

Selected references

- Wenzel et al. Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): a pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention. ISAT. 2021.
 Wenzel K and Fishman M. Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency. ISAT. 2020.
 Hogue A, Becker S, Fishman M, Henderson C, Levy S. Youth OUD Treatment During and After COVID: Increasing Family Involvement across the Services Continuum. ISAT. 2020.
 Fishman M, Wenzel K, Sode S, I Pavlicova M, Lee J, Rotrosen J, Nunes E. Young adults have worse outcomes than older adults: Secondary analysis of a medication trial for opioid use disorder. J Adol Health. 2020.
 Fishman M, Wenzel K, Vol. Hylloberger J, Burgower R. A pilot randomized controlled trial of assertive treatment including family involvement and home delivery of medication for young adults with opioid use disorder.
 Addiction. 2020.
- Woody G, Fishman M. "Medication for Opioid-Addicted Youth What are We Waiting For?" J Adol Health. 67: 9-10. July 2020.
- Monico L, Ludwig A, Lertch E, Dionne R, Fishman M, Schwartz R, Mitchell S. Opioid overdose experiences in a sample of US adolescents and young adults: a thematic analysis. Addiction. 2020.

 Vo H, Burgower R, Rozenberg I, Fishman M. Home-biasad Delivery of R.R. NTX in Youth with Opioid Addiction. J Subst Abuse Treat. 85 (2018) 84–89. PMID: 28867062

 Levy S, et al. A Novel Approach to Treating Adolescents with Opioid Use Disorder in Pediatric Primary Care. Substance Abuse. 2018